A Very Early Rehabilitation Trial (AVERT)
|ClinicalTrials.gov Identifier: NCT01846247|
Recruitment Status : Completed
First Posted : May 3, 2013
Last Update Posted : April 15, 2015
Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days.
Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.
|Condition or disease||Intervention/treatment|
|Stroke||Other: Standard Care + VEM Other: Standard care|
People who suffer a stroke are often left with disabilities such as weakness, or problems with speech, thinking, or control or bodily functions. Severe strokes often result in death. The results of a recent European study indicated that patients who commence mobility training very early after a stroke (Day 1) recover the ability to walk more quickly and return home sooner and in greater numbers than those who start training one week or later after stroke. Recently a phase II (pilot) AVERT study was conducted in which the investigators tested the safety and feasibility of very early mobilisation (European model) Stroke patients in this study randomly received either standard care or very early mobilisation (VEM). The study showed that there was no harm to patients in the VEM group compared to those who had standard care and that delivering VEM was feasible. Consequently, a grant to conduct the larger phase III study, to test the effectiveness of the intervention was obtained.
In this next phase III trial, the investigators aim to look at 2104 patients across stroke care units in city and regional hospitals. Each hospital will be asked to include between 30 and 60 patients per year to the study. All stroke patients admitted to the hospital Stroke Unit or ward at the hospital will be invited to participate. Medical clearance will be obtained for all potential participants. Those unconscious or too ill, together with those already participating in acute drug trials will be excluded. Patients who are able will provide their own consent to participate. Those who are not able to consent for themselves will have a third party (usually a relative) acknowledge their participation in the study. As this is a blinded controlled trial, keeping the assessor and patients unaware of their treatment group is important. The investigators will inform patients that they will have a 50% chance of receiving one of two rehabilitation types during their hospitalization if they decide to participate. Patients in the VEM group will commence treatment within 24 hours of admission to hospital. VEM will be provided by a trained AVERT physiotherapist, and AVERT study nurse and aims to improve functional mobility. The mobilization activities will depend on the patient's functional ability and tolerance to exercise. Patients will be closely monitored prior to mobilization and will only be mobilised if they meet requirements for blood pressure and other vital signs. The number of sessions and the time spent for each patient will vary, however specific targets are to be met according to the intervention protocol. The content and timing of all treatment received by participants in either group will be recorded. The treatment period for this study is from the time of the patients consent, until day 14 or discharge from the stroke unit or ward. (Whichever is earlier). All participants will be assessed at admission to the study, 3 months, and 12 months after their stroke. Information collected by the AVERT physiotherapists and nurses and the assessor will be recorded on individual case record forms and on a secure web based data base. Therapists also add some information to a palm pilot, and then download it onto the secure website. All information collected from patients will be treated as confidential in line with international guidelines and local law.
The primary outcome measure for the study is the number of patients dead and disabled at 3 months after stroke. Other secondary outcome measures include the safety of patients, quality of life, and cost effectiveness. An independent Data Monitoring committee will monitor the safety, conduct and efficacy of the trial. In addition, an independent outcomes committee will be reviewing all events that are reported as serious.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2014 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.|
|Study Start Date :||June 2006|
|Primary Completion Date :||December 2014|
|Study Completion Date :||January 2015|
Placebo Comparator: Standard Care
Standard stroke unit rehabilitation care
|Other: Standard care|
Experimental: Standard Care + VEM
Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
Other: Standard Care + VEM
Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
- modified Rankin Score [ Time Frame: 3 months ]Favorable outcome (0-2) modified Rankin Score
- Safety. Death rate and severity of important medical events [ Time Frame: up until 3 months ]Important medical events (stroke progression, recurrent stroke, falls, angina, myocardial infarction, deep vein thrombosis, pulmonary emboli, pressure sores, chest infections, urinary tract infections, depression) at 3 months.
- Time to unassisted walking over 50 meters and the proportion achieving unassisted walking [ Time Frame: 3 Months ]Achieves walking independently or with supervision over 50 meters
- modified Rankin Score [ Time Frame: 3 months ]Assumption free ordinal approach
- Health related Quality of life [ Time Frame: 12 months ]AQoL
- Cost effectiveness and cost utility [ Time Frame: 12 months ]comprehensive questionaire
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01846247
|Florey Institute for Neuroscience and Mental health|
|Melbourne, Victoria, Australia, 3084|
|Study Director:||Julie Bernhardt, PhD||The Florey Institute of Neuroscience and Mental Health|
|Principal Investigator:||Leonid Churilov, PhD||The Florey Institute of Neuroscience and Mental Health|
|Principal Investigator:||Helen Dewey, MD||Monash University|
|Principal Investigator:||Richard Lindley Dewey, MD||George Institute for Global Health|
|Principal Investigator:||Janice Collier, PhD||The Florey Institute of Neuroscience and Mental Health|
|Principal Investigator:||Amanda Thrift, PhD||Monash University|
|Principal Investigator:||Geoffrey Donnan, MD||The Florey Institute of Neuroscience and Mental Health|